CAR T-cell Therapy

Innovative technologies help you fight cancer and HPV.

Yescarta approved for second-line LBCL in China

Yescarta, the first approved CAR T-cell therapy in China, recently received approval of a new indication of adults with large B-cell lymphoma who have failed first-line immunochemotherapy or relapsed within 12 months after first-line immunochemotherapy (r/r LBCL).

Read More »

Why China being the prior destination for immunotherapy?

China has seen rapid growth in its biotech industry, particularly in the area of CAR T-cell therapy. Many Chinese biotech firms have developed their own CAR T-cell therapies and are actively seeking partnerships with international pharmaceutical companies. As the second-largest country in terms of the number of CAR T-cell therapy clinical trials, China’s research efforts reflect its commitment to advancing this innovative treatment approach.

Moreover, China has implemented various measures to make CAR T-cell therapy more accessible and affordable for patients. These patient-friendly pricing strategies have indeed contributed to making China an attractive destination for international patients for innovative therapies like CAR T-cell therapy. Comparatively, the cost of CAR T-cell therapy in China may be relatively more affordable than in other countries.

Effective and affordable immunotherapy and CAR T-cell Therapy?

Contact us and get detailed information about getting advanced immunotherapy and CAR T-cell therapy for the treatment of solid tumors, blood cancers and HPV infection.